AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33001159 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops (carboxymethyl cellulose, 0.5%)
Number of subjects: 50
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Intensive medical therapy optimization (6-week period)
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Ranolazine
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Ivabradine
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide mononitrate
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Nicorandil
Number of subjects: 200
Study 33496201 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 200
Study 32613374 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Health Education (SHE)
Number of subjects: 350
Study 32613374 — intervention group
Group type: COMPARATOR
Intervention: Telephone Interpersonal Counseling (TIPC)
Number of subjects: 350
Study 34101208 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + PBM
Number of subjects: 26
Study 34101208 — intervention group
Group type: COMPARATOR
Intervention: PT + Sham
Number of subjects: 26
Study 36432510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,000 IU/day for 8 weeks followed by 1000 IU/day for 4 weeks
Number of subjects: 75
Study 36432510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50,000 IU/week for 12 weeks
Number of subjects: 75
Study 36432510 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100,000 IU every other week for 12 weeks
Number of subjects: 75
Study 33985845 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group psychoeducation
Number of subjects: 58
Study 33985845 — intervention group
Group type: COMPARATOR
Intervention: Delay control group
Number of subjects: 58
Study 32493289 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial (AM) drilling
Number of subjects: 300
Study 32493289 — intervention group
Group type: COMPARATOR
Intervention: Transtibial (TT) drilling
Number of subjects: 300
Study 34767068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment DCE‐MRI
Number of subjects: 108
Study 34767068 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on DCE‐MRI findings
Number of subjects: 108
Study 34294537 — intervention group
Group type: EXPERIMENTAL
Intervention: X-ray
Number of subjects: 24
Study 34294537 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 24
Study 34294537 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 24
Study 35665728 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (switch group)
Number of subjects: 7
Study 35665728 — intervention group
Group type: COMPARATOR
Intervention: Nintedanib plus pirfenidone (combination group)
Number of subjects: 7
Study 33177138 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 226
Study 33177138 — intervention group
Group type: COMPARATOR
Intervention: No discontinuation
Number of subjects: 226
Study 33177138 — intervention group
Group type: COMPARATOR
Intervention: Partial discontinuation
Number of subjects: 226
Study 33289436 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 33289436 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 33248570 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U/kg glucose oxidase (GOD)
Number of subjects: 144
Study 33248570 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg virginiamycin (antibiotic)
Number of subjects: 144
Study 33248570 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 144
Study 33433147 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided trigger point injections (TPI)
Number of subjects: 60
Study 33433147 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane (TAP) block
Number of subjects: 60
Study 32366214 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention based on comprehensive geriatric assessment
Number of subjects: 242
Study 32366214 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 242
Study 34424337 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS-6
Number of subjects: 603
Study 34424337 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS-12
Number of subjects: 603
Study 34424337 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 603
Study 34424337 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 603
Study 34051626 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 267
Study 34051626 — intervention group
Group type: COMPARATOR
Intervention: Present-Centered Therapy (PCT)
Number of subjects: 267
Study 32164579 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with temozolomide (Arm A)
Number of subjects: 120
Study 32164579 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide alone (Arm B)
Number of subjects: 120
Study 35088616 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires administered via paper booklets, interactive voice response system, or tablet web survey
Number of subjects: 1830
Study 35088616 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes Measurement Information System scales
Number of subjects: 1830
Study 34447897 — intervention group
Group type: EXPERIMENTAL
Intervention: Kusamala Program (4-day hospital-based counseling program for caregivers of children with SAM)
Number of subjects: 172
Study 34447897 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm (control group)
Number of subjects: 172
Study 36029969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1097
Study 32896653 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin-PT 25 μg
Number of subjects: 102
Study 32896653 — intervention group
Group type: EXPERIMENTAL
Intervention: Viaskin-PT 50 μg
Number of subjects: 102
Study 32896653 — intervention group
Group type: COMPARATOR
Intervention: Laser + Viaskin-placebo
Number of subjects: 102
Study 36460293 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS-tDCS
Number of subjects: 84
Study 36460293 — intervention group
Group type: COMPARATOR
Intervention: single-tDCS
Number of subjects: 84
Study 36460293 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 84
Study 36460293 — intervention group
Group type: COMPARATOR
Intervention: single-rTMS
Number of subjects: 84
Study 33794969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivomixx® probiotic (10 billion CFU/ml, 1 ml/day for 30 days)
Number of subjects: 6144
Study 33794969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (organoleptically similar)
Number of subjects: 6144
Study 34860350 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based scheduled gradual reduction (SGR) intervention
Number of subjects: 0
Study 32791618 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual reality assisted vestibular rehabilitation training (VRT)
Number of subjects: 98
Study 32791618 — intervention group
Group type: COMPARATOR
Intervention: Conventional vestibular rehabilitation training (VRT)
Number of subjects: 98
Study 35939096 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID Impact survey follow-up after approximately 11.4 months
Number of subjects: 74
Study 35939096 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS-depression scale
Number of subjects: 74
Study 35939096 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS-anxiety scale
Number of subjects: 74
Study 35939096 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of mental well-being
Number of subjects: 74
Study 34379915 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine (100 µg, two injections, 28 days apart)
Number of subjects: 3732
Study 34379915 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 3732
Study 34379915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3732
Study 36206951 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel, faith-based intervention linking Catholic parishes to local parks
Number of subjects: 1204
Study 34349370 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Protector™
Number of subjects: 0
Study 34349370 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme™
Number of subjects: 0
Study 35439548 — intervention group
Group type: EXPERIMENTAL
Intervention: WW+ginger (ginger footbaths)
Number of subjects: 28
Study 35439548 — intervention group
Group type: COMPARATOR
Intervention: WW (warm water footbaths)
Number of subjects: 28
Study 34269848 — intervention group
Group type: EXPERIMENTAL
Intervention: MB02 (3 mg/kg IV dose)
Number of subjects: 48
Study 34269848 — intervention group
Group type: COMPARATOR
Intervention: Reference bevacizumab (3 mg/kg IV dose)
Number of subjects: 48